Company
immunogenesis
Ignite a New Approach to Cancer Care
Also known as ImmunoGenesis, Inc
- Business model
- B2B
- Legal name
- ImmunoGenesis, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
We are rapidly translating the most cutting-edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy.
Funding snapshot
- Total raised
- $50.2MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $5.7M2024-12-18
Funding rounds
- Round, 2024
- $5.7M2024-12-18, SEC form D sold, 2 investors
- Round, 2024
- $44.4M2024-03-18, SEC form D sold, 88 investors
Products
- Web
- IMGS-001
Loading relationship preview